HER2 WT Citations (32)
Originally described in: Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC Cancer Cell. 2004 Nov . 6(5):459-69. PubMed Journal
Articles Citing HER2 WT
| Articles |
|---|
| Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Merkhofer EC, Cogswell P, Baldwin AS. Oncogene. 2010 Feb 25. 29(8):1238-48. PubMed |
| Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells. Li YW, Zhu GY, Shen XL, Chu JH, Yu ZL, Fong WF. Cancer Chemother Pharmacol. 2011 Nov;68(5):1315-23. doi: 10.1007/s00280-011-1624-x. Epub 2011 Apr 3. PubMed |
| Role of epidermal growth factor receptor signaling in the interaction of Neisseria meningitidis with endothelial cells. Slanina H, Mundlein S, Hebling S, Schubert-Unkmeir A. Infect Immun. 2014 Mar;82(3):1243-55. doi: 10.1128/IAI.01346-13. Epub 2013 Dec 30. PubMed |
| Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. Carpenter RL, Paw I, Dewhirst MW, Lo HW. Oncogene. 2015 Jan 29;34(5):546-57. doi: 10.1038/onc.2013.582. Epub 2014 Jan 27. PubMed |
| Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells. Hosonaga M, Arima Y, Sugihara E, Kohno N, Saya H. Cancer Sci. 2014 Jul;105(7):779-87. doi: 10.1111/cas.12427. Epub 2014 Jun 2. PubMed |
| Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. Huang W, Wu QD, Zhang M, Kong YL, Cao PR, Zheng W, Xu JH, Ye M. Cancer Lett. 2015 Jan 28;356(2 Pt B):862-71. doi: 10.1016/j.canlet.2014.10.040. Epub 2014 Nov 4. PubMed |
| Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression. Ko YS, Cho SJ, Park J, Kim Y, Choi YJ, Pyo JS, Jang BG, Park JW, Kim WH, Lee BL. Br J Cancer. 2015 Oct 20;113(8):1186-96. doi: 10.1038/bjc.2015.273. Epub 2015 Oct 8. PubMed |
| Type II cGMP-dependent protein kinase directly inhibits HER2 activation of gastric cancer cells. Zhu M, Yao X, Wu M, Qian H, Wu Y, Chen Y. Mol Med Rep. 2015 Dec 17. doi: 10.3892/mmr.2015.4688. PubMed |
| Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Ma S, Henson ES, Chen Y, Gibson SB. Cell Death Dis. 2016 Jul 21;7:e2307. doi: 10.1038/cddis.2016.208. PubMed |
| An in-vivo study for targeted delivery of copper-organic complex to breast cancer using chitosan polymer nanoparticles. Pramanik A, Laha D, Dash SK, Chattopadhyay S, Roy S, Das DK, Pramanik P, Karmakar P. Mater Sci Eng C Mater Biol Appl. 2016 Nov 1;68:327-337. doi: 10.1016/j.msec.2016.05.014. Epub 2016 May 10. PubMed |
| Let-7 Status is Crucial for PARP1 Expression in HER2-overexpressing Breast Tumors. Wielgos ME, Rajbhandari R, Cooper TS, Wei S, Nozell SE, Yang ES. Mol Cancer Res. 2016 Dec 28. pii: molcanres.0287.2016. doi: 10.1158/1541-7786.MCR-16-0287-T. PubMed |
| Establishment of a spontaneous metastasis tumor model for human ErbB-2 vaccine. Dai X, He Y, Yao W, Gao X. Biomed Pharmacother. 2017 Apr;88:991-998. doi: 10.1016/j.biopha.2017.01.099. Epub 2017 Feb 6. PubMed |
| Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Napolitano S, Martini G, Martinelli E, Belli V, Parascandolo A, Laukkanen MO, Sforza V, Morgillo F, Ciardiello D, Ciardiello F, Troiani T. Oncotarget. 2017 Jun 27. doi: 10.18632/oncotarget.18749. PubMed |
| Switching of the substrate specificity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating 2 oncogenic pathways. Li H, Yang D, Ning S, Xu Y, Yang F, Yin R, Feng T, Han S, Guo L, Zhang P, Qu W, Guo R, Song C, Xiao P, Zhou C, Xu Z, Sun JP, Yu X. FASEB J. 2018 Jan;32(1):73-82. doi: 10.1096/fj.201700418R. Epub 2017 Aug 24. PubMed |
| Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Napolitano S, Martini G, Martinelli E, Belli V, Parascandolo A, Laukkanen MO, Sforza V, Morgillo F, Ciardiello D, Ciardiello F, Troiani T. Oncotarget. 2017 Jun 27;8(40):67592-67604. doi: 10.18632/oncotarget.18749. eCollection 2017 Sep 15. PubMed |
| Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, Lo HW. Oncotarget. 2017 May 22;8(43):73947-73963. doi: 10.18632/oncotarget.18166. eCollection 2017 Sep 26. PubMed |
| Differential regulation of human monocytes and NK cells by antibody-opsonized tumors. Yin J, Albers AJ, Smith TS, Riddell GT, Richards JO. Cancer Immunol Immunother. 2018 Aug;67(8):1239-1250. doi: 10.1007/s00262-018-2179-z. Epub 2018 May 31. PubMed |
| Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Kurmi K, Hitosugi S, Yu J, Boakye-Agyeman F, Wiese EK, Larson TR, Dai Q, Machida YJ, Lou Z, Wang L, Boughey JC, Kaufmann SH, Goetz MP, Karnitz LM, Hitosugi T. Cell Metab. 2018 Dec 4;28(6):833-847.e8. doi: 10.1016/j.cmet.2018.08.008. Epub 2018 Aug 30. PubMed |
| Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. Gao P, Wang X, Jin Y, Hu W, Duan Y, Shi A, Du Y, Song D, Yang M, Li S, Han B, Zhao G, Zhang H, Fan Z, Miao QR. Breast Cancer Res. 2018 Sep 12;20(1):112. doi: 10.1186/s13058-018-1028-5. PubMed |
| HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFkappaB-dependent way. Wang W, Gao Y, Hai J, Yang J, Duan S. Biosci Rep. 2019 Mar 19;39(3). pii: BSR20180829. doi: 10.1042/BSR20180829. Print 2019 Mar 29. PubMed |
| HER2 Regulates Cancer Stem Cell Activities via the Wnt Signaling Pathway in Gastric Cancer Cells. Jung DH, Bae YJ, Kim JH, Shin YK, Jeung HC. Oncology. 2019;97(5):311-318. doi: 10.1159/000502845. Epub 2019 Sep 24. PubMed |
| Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses. Jeon I, Lee JM, Shin KS, Kang T, Park MH, Seo H, Song B, Koh CH, Choi J, Shin YK, Kim BS, Kang CY. Vaccines (Basel). 2020 Jul 22;8(3). pii: vaccines8030403. doi: 10.3390/vaccines8030403. PubMed |
| Excessive All-Trans Retinoic Acid Inhibits Cell Proliferation Through Upregulated MicroRNA-4680-3p in Cultured Human Palate Cells. Yoshioka H, Ramakrishnan SS, Shim J, Suzuki A, Iwata J. Front Cell Dev Biol. 2021 Jan 28;9:618876. doi: 10.3389/fcell.2021.618876. eCollection 2021. PubMed |
| Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer. Yang Y, Leonard M, Luo Z, Yeo S, Bick G, Hao M, Cai C, Charif M, Wang J, Guan JL, Lower EE, Zhang X. Cell Rep. 2021 Mar 9;34(10):108822. doi: 10.1016/j.celrep.2021.108822. PubMed |
| Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells. Chen Y, Wang R, Huang S, Henson ES, Bi J, Gibson SB. Cancers (Basel). 2021 Mar 2;13(5). pii: cancers13051038. doi: 10.3390/cancers13051038. PubMed |
| Nrg1beta Released in Remote Ischemic Preconditioning Improves Myocardial Perfusion and Decreases Ischemia/Reperfusion Injury via ErbB2-Mediated Rescue of Endothelial Nitric Oxide Synthase and Abrogation of Trx2 Autophagy. Kundumani-Sridharan V, Subramani J, Owens C, Das KC. Arterioscler Thromb Vasc Biol. 2021 Aug;41(8):2293-2314. doi: 10.1161/ATVBAHA.121.315957. Epub 2021 May 27. PubMed |
| HER2-PI9 and HER2-I12: two novel and functionally active splice variants of the oncogene HER2 in breast cancer. Hart V, Silipo M, Satam S, Gautrey H, Kirby J, Tyson-Capper A. J Cancer Res Clin Oncol. 2021 Oct;147(10):2893-2912. doi: 10.1007/s00432-021-03689-1. Epub 2021 Jun 16. PubMed |
| HER2 c-Terminal Fragments Are Expressed via Internal Translation of the HER2 mRNA. Godfrey JD, Hejazi D, Du X, Wei C, Rao E, Gomez CM. Int J Mol Sci. 2022 Aug 23;23(17):9549. doi: 10.3390/ijms23179549. PubMed |
Engineered cell entry links receptor biology with single-cell genomics.
Yu B, Shi Q, Belk JA, Yost KE, Parker KR, Li R, Liu BB, Huang H, Lingwood D, Greenleaf WJ, Davis MM, Satpathy AT, Chang HY.
Cell. 2022 Dec 22;185(26):4904-4920.e22. doi: 10.1016/j.cell.2022.11.016. Epub 2022 Dec 13.
PubMed
Associated Plasmids |
| The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells. Kollara A, Burt BD, Ringuette MJ, Brown TJ. Cell Signal. 2023 Jun;106:110634. doi: 10.1016/j.cellsig.2023.110634. Epub 2023 Feb 23. PubMed |
| Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue. Corogeanu D, Zaki K, Beavil AJ, Arnold JN, Diebold SS. PLoS One. 2023 Mar 13;18(3):e0282831. doi: 10.1371/journal.pone.0282831. eCollection 2023. PubMed |
| PD-1(Hi) CAR-T cells provide superior protection against solid tumors. Sailer CJ, Hong Y, Dahal A, Ryan AT, Mir S, Gerber SA, Reagan PM, Kim M. Front Immunol. 2023 Jun 14;14:1187850. doi: 10.3389/fimmu.2023.1187850. eCollection 2023. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.